Cholecystokinin in anxiety
European Neuropsychopharmacology, ISSN: 0924-977X, Vol: 6, Issue: 4, Page: 263-280
1996
- 113Citations
- 20Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations113
- Citation Indexes113
- 113
- CrossRef87
- Captures20
- Readers20
- 20
Review Description
Cholecystokinin (CCK) plays an important role in both the alimentary tract and the central nervous system (CNS). At present it seems to be the most abundant neuropeptide in the CNS. This paper reviews the CCK neuronal system and its interactions with γ-aminobutyric acid (GABA) and serotonin (5-hydroxytryptamine; 5-HT). In addition, its putative role in anxiety will be discussed on the basis of animal data and studies in healthy volunteers and panic disorder patients. According to these investigations, the CCK 4 challenge test fulfills most criteria for an ideal panicogenic agent and evidence has been found that CCK B receptor antagonists might possess anxiolytic properties in man.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S0924977X96000387; http://dx.doi.org/10.1016/s0924-977x(96)00038-7; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=0030294164&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/8985709; https://linkinghub.elsevier.com/retrieve/pii/S0924977X96000387; http://linkinghub.elsevier.com/retrieve/pii/S0924977X96000387; http://api.elsevier.com/content/article/PII:S0924977X96000387?httpAccept=text/xml; http://api.elsevier.com/content/article/PII:S0924977X96000387?httpAccept=text/plain
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know